English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

∆9-Tetrahydrocannabinol (∆9-THC), an active ingredient of marijuana, evokes a number of biological effects including anti-cancer and anti-estrogenic actions. We and others have so far focused on and investigated the latter action. We recently reported that ∆9-THC up-regulates the expression of estrogen receptor β (ERβ, ESR2), resulting in the abrogation of 17β-estradiol (E2)-mediated ERα signaling (Takeda et al., Chem. Res. Toxicol., 26, 1073-1079, 2013). This finding may shed light on the possible endocrine-disrupting mechanism(s) employed by cannabinoids including ∆9-THC. Although previous studies have suggested that HU-210, a synthetic analog of ∆9-THC, evokes a set of endocrine alterations closely related to those of ∆9-THC, none have examined the effects of cannabinoids with a focus on the expression of ERβ, a “suppressive” molecule for ERα-mediated signaling. Thus, we herein determined whether HU-210 is also an endocrine modifier similar to ∆9-THC using ERα-positive MCF-7 cells in which the expression of ERβ is maintained at very low levels. The results of the present study revealed that HU-210, despite having a similar structure to ∆9-THC, did not modulate E2/ERα signaling or induce ERβ.

HU-210, a synthetic analog of ∆<sup>9</sup>-THC, is not a modifier of estrogen signaling in MCF-7 human breast cancer cells